Actively Recruiting
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Led by Gruppo Italiano Malattie EMatologiche dell'Adulto · Updated on 2025-09-10
159
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy. A minimum of 159 patients is required. Overall study duration is estimated in 36 months.
CONDITIONS
Official Title
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age equal to or greater than 18 years old at the time of SVd initiation
- Signed informed consent (if applicable)
- Diagnosis of symptomatic Multiple Myeloma as defined by the International Myeloma Working Group (IMWG) criteria
- Relapse after one to three lines of therapy
- Treatment with SVd (having received at least one dose) at the time SVd entered clinical practice in Italy
- Prior treatment with and refractoriness to lenalidomide
You will not qualify if you...
- Previous exposure to selinexor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aou Careggi - Sod Ematologia
Florence, Italy
Actively Recruiting
Research Team
P
Paola Fazi
CONTACT
E
Enrico Crea
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here